JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $76

Benzinga · 1d ago
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and raises the price target from $72 to $76.